Clinical Trials | April 30, 2026
Zealand Pharma and Roche charge into Phase 3 with obesity drug bet
The Danish biotech company confirmed the global study will begin in the second half of 2026
The Danish biotech company confirmed the global study will begin in the second half of 2026
Health innovations are viewed more positively than food and agricultural technologies
Landmark agreement opens market access, mobility pathways, and institutional collaboration for Ayurveda, Yoga, and holistic healthcare services
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Rs. 40 cr buyback, 200% dividend announced
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
Subscribe To Our Newsletter & Stay Updated
